Cellcyte Competitors

Summary

Cellcyte Genetics competes with PVH Corp, Air Lease, Cedar Fair, Rocky Brands, and Canada Goose; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Cellcyte Genetics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Cellcyte Genetics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Cellcyte Genetics competition on your existing holdings.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cellcyte Genetics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.

Hype

Prediction

Low	Estimated	High
0.00	0.00	0.00

Details

Intrinsic

Valuation

Low	Real	High
0.00	0.00	0.00

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Cellcyte Genetics. Your research has to be compared to or analyzed against Cellcyte Genetics' peers to derive any actionable benefits. When done correctly, Cellcyte Genetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Cellcyte Genetics.

Cellcyte Genetics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cellcyte Genetics and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Cellcyte and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cellcyte Genetics does not affect the price movement of the other competitor.

	PVH	AL	FUN	RCKY	GOOS	TLF	ASR
PVH		-0.27	0.56	0.1	0.7	-0.33	-0.28	PVH
AL	-0.27		0.24	-0.51	-0.55	0.33	0.75	AL
FUN	0.56	0.24		-0.33	0.35	-0.33	0.26	FUN
RCKY	0.1	-0.51	-0.33		0.35	-0.24	-0.14	RCKY
GOOS	0.7	-0.55	0.35	0.35		-0.45	-0.33	GOOS
TLF	-0.33	0.33	-0.33	-0.24	-0.45		0.16	TLF
ASR	-0.28	0.75	0.26	-0.14	-0.33	0.16		ASR
	PVH	AL	FUN	RCKY	GOOS	TLF	ASR

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

ASR	+ 0.75	AL
GOOS	+ 0.7	PVH
FUN	+ 0.56	PVH
GOOS	+ 0.35	FUN
GOOS	+ 0.35	RCKY
TLF	+ 0.33	AL

High negative correlations

GOOS	- 0.55	AL
RCKY	- 0.51	AL
TLF	- 0.45	GOOS
ASR	- 0.33	GOOS
TLF	- 0.33	FUN
RCKY	- 0.33	FUN

Risk-Adjusted Indicators

There is a big difference between Cellcyte OTC Stock performing well and Cellcyte Genetics OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cellcyte Genetics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
PVH	1.70	(0.24)	0.00	(0.06)	0.00	0.00	2.83	(2.81)	28.29
AL	1.18	0.31	0.15	3.22	1.35	(1.30)	2.61	(2.03)	7.87
FUN	1.14	(0.04)	(0.04)	(0.01)	1.46	(1.18)	2.18	(1.98)	6.91
RCKY	2.62	(0.06)	0.00	0.02	4.04	(2.59)	6.10	(4.76)	22.46
GOOS	2.43	0.03	0.00	0.03	0.00	0.00	4.90	(4.98)	15.30
TLF	1.16	(0.04)	0.00	0.19	0.00	0.00	2.48	(2.64)	7.06
ASR	1.28	0.16	0.09	0.34	1.37	(1.45)	2.69	(2.50)	6.80

Cellcyte Genetics Competitive Analysis

The better you understand Cellcyte Genetics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cellcyte Genetics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cellcyte Genetics' competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	PVH	AL	FUN	RCKY	GOOS	TLF	ASR
	0.53 106.31 PVH	0.19 48.73 Air	0.47 38.46 Cedar	2.71 25.89 Rocky	0.36 11.24 Canada	0.65 4.61 Tandy	1.12 307.14 Grupo
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Not too volatile	Not too volatile	Somewhat reliable	Very steady
Market Performance (90 Days Performance)	Very Weak	Good	Very Weak	Very Weak	Very Weak	Very Weak	OK
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Below Average	Below Average	Very Low	Very Small	Very Low	Very Small
Current Valuation (Equity Enterprise Value)	Fairly Valued	Under Valued	Under Valued	Over Valued	Under Valued	Under Valued	Fairly Valued
Buy or Sell Advice (Average Analysts Consensus)	Buy	Strong Buy	Strong Buy	Hold	Hold	Strong Sell	Buy
Trade Advice (90 Days Macroaxis Advice)	Strong Hold	Strong Buy	Strong Hold	Cautious Hold	Strong Sell	Strong Sell	Buy
Current Ratio	1.35 X	0.90 X	0.94 X	2.56 X	2.42 X	3.96 X	3.70 X
Net Asset	11.17 B	30.45 B	2.28 B	490.83 M	1.59 B	72.14 M	70.56 B
Profit Margin	0.07 %	0.23 %	0.07 %	0.02 %	0.04 %	0.05 %	0.40 %
EBITDA	1.12 B	1.81 B	504.51 M	50.6 M	135.5 M	9.04 M	17.31 B
Current Valuation	8.97 B	24.13 B	4.27 B	368.79 M	1.68 B	35.99 M	96.14 B
Operating Margin	0.14 %	0.53 %	0.14 %	0.14 %	0.33 %	0.08 %	0.53 %
Price To Book	1.19 X	0.76 X	N/A	0.88 X	3.61 X	0.70 X	3.49 X
Retained Earnings	5.41 B	3.87 B	307.67 M	151.58 M	316.5 M	63.66 M	24.7 B
Current Asset	405.3 M	1.24 B	184.03 M	129.22 M	243.04 M	47.56 M	2.99 B
Five Year Return	0.13 %	1.40 %	6.52 %	1.84 %	N/A	N/A	2.36 %
Beta	2.2	1.65	1.42	1.98	1.41	0.85	0.79
Number Of Employees	17 K	163	3.35 K	2.06 K	4.76 K	389	1.48 K
Shares Outstanding	57.69 M	111.37 M	51.03 M	7.42 M	45.93 M	8.4 M	30 M
Cash Flow From Operations	969.4 M	1.75 B	323.03 M	73.58 M	116.3 M	4.54 M	13.58 B
Annual Yield	0 %	0.02 %	0.03 %	0.02 %	N/A	N/A	0.02 %
Total Debt	3.53 B	19.18 B	2.36 B	181.22 M	754 M	9.43 M	12.25 B
Return On Equity	0.13	0.089	N/A	0.0475	0.0901	0.0699	0.21
Return On Asset	0.0509	0.0296	0.0968	0.0467	0.0416	0.0392	0.13
Book Value Per Share	88.82 X	64.49 X	(11.43) X	30.16 X	4.04 X	6.71 X	149.82 X
Number Of Shares Shorted	1.74 M	5.31 M	3.02 M	302.73 K	10.97 M	3.69 K	124.32 K
Current Liabilities	114.36 M	1.07 B	198.67 M	14.75 M	85.9 M	8.33 M	506.69 M
Total Asset	11.17 B	30.45 B	2.28 B	490.83 M	1.59 B	72.14 M	70.56 B
Debt To Equity	0.71 %	2.85 %	76.24 %	1.43 %	1.98 %	0.21 %	0.33 %
Short Ratio	2.11 X	1.95 X	14.57 X	9.76 X	11.91 X	1.14 X	2.96 X
Target Price	129.14	54.0	51.67	26.0	12.49	7.5	315.59
Last Dividend Paid	0.15	0.81	1.2	0.62	N/A	N/A	N/A
Shares Owned By Institutions	99.30 %	91.37 %	64.92 %	75.99 %	98.49 %	56.48 %	12.50 %
Market Capitalization	6.13 B	5.43 B	1.97 B	192.04 M	1.09 B	38.72 M	9.57 B
Price To Earning	3.83 X	8.71 X	26.81 X	9.50 X	36.57 X	187.50 X	140.93 X
Price To Earnings To Growth	0.21 X	0.91 X	3.72 X	1.62 X	3.02 X	N/A	18.25 X
Price To Sales	0.66 X	2.01 X	1.11 X	0.43 X	0.83 X	0.51 X	0.37 X
Net Income	663.6 M	614.62 M	124.56 M	10.43 M	68.9 M	3.77 M	10.2 B
Earnings Per Share	10.76 X	5.14 X	2.42 X	1.41 X	0.36 X	0.45 X	20.35 X
Shares Owned By Insiders	0.74 %	6.51 %	1.70 %	7.48 %	1.51 %	5.23 %	1.47 %
Revenue	9.22 B	2.68 B	1.8 B	461.83 M	1.22 B	76.23 M	25.82 B
Working Capital	488.2 M	(843.51 M)	(193.89 M)	186.64 M	510.8 M	42.32 M	13.91 B
Cash And Equivalents	550.7 M	766.42 M	101.19 M	5.8 M	81.8 M	5.59 M	13.17 B
Cash Per Share	10.72 X	9.13 X	2.20 X	0.79 X	0.78 X	0.68 X	463.91 X
Gross Profit	5.12 B	1.35 B	788.83 M	226.42 M	733.6 M	47 M	14.64 B
Day Typical Price	106.84	49.01	38.5	26.26	11.22	4.67	306.35
Accumulation Distribution	0.0207	14173.93	0.0266	789.81	0.0299	0.0396	416.15
Market Facilitation Index	2.24	0.0	1.04	1.0E-4	0.34	0.19	2.0E-4
Daily Balance Of Power	0.25	0.0826	(0.17)	(0.64)	0.1176	(0.16)	0.7375
Period Momentum Indicator	0.56	0.09	(0.18)	(0.72)	0.04	(0.03)	3.4
Rate Of Daily Change	1.01	1.0	1.0	0.97	1.0	0.99	1.01
Day Median Price	107.1	49.16	38.52	26.45	11.21	4.71	305.96
Price Action Indicator	(0.51)	(0.38)	(0.15)	(0.92)	0.05	(0.11)	2.88
Relative Strength Index	29.74	70.22	48.44	52.65	37.76	62.37	75.13
Coefficient Of Variation	(2,945)	489.92	23894.49	7147.1	(14,049)	(3,398)	763.01
Mean Deviation	1.7	1.18	1.14	2.62	2.43	1.16	1.28
Jensen Alpha	(0.24)	0.3085	(0.04)	(0.06)	0.0303	(0.04)	0.1635
Total Risk Alpha	(0.43)	0.1636	(0.14)	(0.31)	(0.33)	(0.21)	0.0474
Sortino Ratio	N/A	0.1521	(0.04)	(0)	N/A	N/A	0.093
Downside Variance	N/A	2.83	2.27	16.93	N/A	N/A	2.22
Standard Deviation	3.27	1.59	1.45	3.69	3.15	1.63	1.58
Kurtosis	32.53	1.44	0.6748	4.9	0.3656	0.6907	0.2104
Potential Upside	2.83	2.61	2.18	6.1	4.9	2.48	2.69
Treynor Ratio	(0.06)	3.22	(0.01)	0.024	0.0303	0.1928	0.3414
Maximum Drawdown	28.29	7.87	6.91	22.46	15.3	7.06	6.8
Variance	10.69	2.52	2.11	13.61	9.91	2.67	2.5
Market Risk Adjusted Performance	(0.05)	3.23	0.004	0.034	0.0403	0.2028	0.3514
Risk Adjusted Performance	(0.01)	0.1323	0.0083	0.017	0.0036	(0.01)	0.0871
Skewness	(4.74)	(0.26)	(0.14)	(1.09)	0.2315	0.1274	0.1216
Semi Deviation	N/A	1.35	1.46	4.04	N/A	N/A	1.37
Information Ratio	(0.05)	0.1609	(0.04)	(0)	(0.03)	(0.07)	0.0877
Value At Risk	(2.81)	(2.03)	(1.98)	(4.76)	(4.98)	(2.64)	(2.50)
Expected Short fall	N/A	(1.30)	(1.18)	(2.59)	N/A	N/A	(1.45)
Downside Deviation	N/A	1.68	1.51	4.11	N/A	N/A	1.49
Semi Variance	N/A	1.83	2.13	16.33	N/A	N/A	1.87

Cellcyte Genetics Competition Performance Charts

Five steps to successful analysis of Cellcyte Genetics Competition

Cellcyte Genetics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cellcyte Genetics in relation to its competition. Cellcyte Genetics' competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Cellcyte Genetics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cellcyte Genetics' competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cellcyte Genetics, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Cellcyte Genetics position

In addition to having Cellcyte Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Sovereign ETFs Thematic Idea Now

Broad Sovereign ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.

View All Next

Launch

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Consideration for investing in Cellcyte OTC Stock

If you are still planning to invest in Cellcyte Genetics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cellcyte Genetics' history and understand the potential risks before investing.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Stocks Directory Find actively traded stocks across global markets

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC